ArticleBreast cancer research : BCR2026
Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lymphatic Endothelial Cells in Health and Disease.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBreast cancer patients who undergo regional nodal irradiation therapy (RNI) following neoadjuvant chemotherapy and mastectomy or lumpectomy with axillary lymph node dissection (ALND) frequently encounter breast cancer-related lymphedema (BCRL). Early detection and treatment can significantly improve outcomes. Previously, near-infrared fluorescence lymphatic imaging (NIRF-LI) detection of dermal backflow, or retrograde lymphatic flow into initial lymphatics, was shown to precede clinical BCRL diagnosis by 8–23 months. Herein, we hypothesize that lymphatic pump failure is responsible for dermal backflow and may be a target to prevent onset of BCRL symptoms.
methodsArm lymphatics in 51 patients with locally advanced breast cancer were visualized with NIRF-LI in a prospective, longitudinal, observational clinical cohort study. Lymphatic pumping frequencies were measured to investigate pumping changes during and after breast cancer treatment. Lymphatic pumping was quantified at five timepoints: after neoadjuvant chemotherapy, but before breast cancer excision and ALND, again at four weeks post-ALND, and at 6, 12, and 18 months post-RNI. Repeated measures mixed-effects analysis was used to compare the mean pumping frequencies amongst all time points. Additionally, pairwise comparisons between any two time points were performed using Wilcoxon matched-pairs signed rank test.
resultsAs time lapsed after surgical treatment and RNI, ipsilateral dorsal forearm, ipsilateral ventral forearm, and ventral axilla pumping failure preceded the appearance of dermal backflow and clinically diagnosed BCRL, suggesting that lymphatic pumping dysfunction is the first step in BCRL development.
conclusionsThis study suggests that impairment of the intrinsic lymph pump may be responsible for the onset of clinical BCRL symptoms, and therefore represents a target for prevention of cancer-acquired lymphedema. Future research is needed to understand the molecular determinants of the intrinsic lymphatic pump, and how cancer treatments and interventions can impact them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.